Ligand-Free Palladium-Catalyzed Oxyarylation of Dihydronaphthal­enes and Chromenequinone with o-Iodophenols and 3-Iodolawsone in PEG-400: An Efficient Synthesis of 5-Carbapterocarpans and Pterocarpanquinones

Abstract

Dihydronaphthalenes were oxyarylated with o-iodophenols, in PEG-400 at 140 or 170 °C, leading regio- and stereoselectively to 5-carbapterocarpans. By using Pd(OAc)₂ (5–10 mol%) as precatalyst and Ag₂CO₃ (1.1 equiv) as base (conditions A), products were obtained in good to excellent chemical yields, in 5–30 minutes, irrespective of the pattern of substitution the starting materials. Alternatively, when p-hydroxyacetophenone oxime derived palladacycle (1 mol%) was used as precatalyst, and dicyclohexylamine (2 equiv) was used as base (silver-free, conditions B), the corresponding adducts were obtained in moderate to good yields, in 0.5 to 4 hours. Finally, the oxyarylation of dihydronaphthalenes­ and chromenquinone with o-iodophenols and 3-iodolawsone in PEG-400 under conditions A led regio- and stereoselectively to the formation of carbapterocarpanquinones and pterocarpanquinones in moderate yield.

Key words

oxyarylation reaction - PEG - carbapterocarpans - pterocarpanquinones - oxygen heterocycles

• References

• 1 Horino H, Inoue N. J. Chem. Soc., Chem. Commun. 1976; 500
• 2a Ishiguro M, Tatsuoka T, Nakatsuka N. Tetrahedron Lett. 1982; 23: 3859
• 2b Breytenbach JC, Rall GJ. H. J. Chem. Soc., Perkin Trans. 1 1980; 1804
• 2c Narkhede DD, Iyer PR, Iyer CS. R. J. Nat. Prod. 1989; 52: 502
• 2d Subburaj K, Katoch R, Murugesh MG, Trivedi GK. Tetrahedron 1997; 53: 12621
• 2e Coelho AS, Vasconcellos ML. A. A, Simas AB, Rabi JA, Costa PR. R. Synthesis 1992; 914
• 2f Lichtenfelos RA, Coelho AL, Costa PR. R. J. Chem. Soc., Perkin Trans. 1 1995; 949
• 2g da Silva AJ. M, Melo PA, Silva NM. V, Brito FV, Buarque CD, Souza DV, Rodrigues VP, Poças ES. C, Albuquerque EX, Costa PR. R. Bioorg. Med. Chem. Lett. 2001; 11: 283
• 2h da Silva AJ. M, Buarque CD, Brito FV, Aurelian L, Lopes DV. S, Macedo LF, Malkas LH, Hickey RJ, Lopes DV. S, Noel F, Murakami YL. B, Silva NM. V, Melo PA, Caruso RR. B, Castro NG, Costa PR. R. Bioorg. Med. Chem. 2002; 10: 2731
• 2i da Silva AJ. M, Netto CD, Costa PR. R. J. Braz. Chem. Soc. 2004; 15: 979
• 3a Larock RC. U. S. Pat. US5721371(A), 1998
• 3b Emrich DE, Larock RC. J. Organomet. Chem. 2004; 689: 3756
• 4a Kiss L, Kurtan T, Antus S, Brunner H. ARKIVOC 2003; (v): 69
• 4b Catellani M, Del Rio A. Russ. Chem. Bull. 1998; 47: 928
• 5a Buarque CD, Pinho VD, Vaz BG, Eberlin MN, da Silva AJ. M, Costa PR. R. J. Organomet. Chem. 2010; 695: 2062
• 5b Fernandes Tde A, Gontijo Vaz B, Eberlin MN, da Silva AJ. M, Costa PR. R. J. Org. Chem. 2010; 75: 7085
• 6 Leão RA, Pinho VD, Coelho AS, Buarque CD, Moraes P, Alonso DA, Nájera C, Costa PR. R. Eur. J. Org. Chem. 2011; 3313
• 7a Buarque CD, Salustiano EJ, Fraga KC, Alves BR. M, Costa PR. R. Eur. J. Med. Chem. 2014; 190
• 7b Buarque CD, Militão GC. G, Lima DJ. B, Costa-Lotufo LV, Pessoa C, Moraes MO, Cunha-Junior EF, Torres-Santos EC, Netto CD, Costa PR. R. Bioorg. Med. Chem. 2011; 19: 6885
• 7c Maia RC, Vasconcelos FC, Bacelar TS, Salustiano EJ, Silva LF. R, Pereira DL, Moellman-Coelho A, Netto CD, Silva AJ, Rumjanek VM, Costa PR. R. Invest. New Drugs 2011; 29: 1143
• 7d Netto CD, da Silva AJ. M, Salustiano EJ. S, Bacelar TS, Riça IG, Cavalcante MC. V, Rumjanek VM, Costa PR. R. Bioorg. Med. Chem. 2010; 18: 1610
• 7e de Moraes GN, Castro CP, Salustiano EJ, Dumas ML, Costas F, Lam EW, Costa PR. R, Maia RC. Int. J. Oncol. 2014; 45: 1949
• 7f Costa L, Pinheiro RO, Dutra PM. L, Santos RF, Cunha-Júnior EF, Torres-Santos EC, da Silva AJ. M, Costa PR. R, Da-Silva SA. G. PLoS One 2014; 9: e109672
• 7g Bacelar TS, da Silva AJ. M, Costa PR. R, Rumjanek VM. Anti-Cancer Drugs 2013; 24: 73
• 7h Reis FR. S, Faria FC. C, Castro CP, de Souza PS, Vasconcelos FC, Bello RD, da Silva AJ. M, Costa PR. R, Maia RC. Anti-Cancer Agents Med. Chem. 2013; 13: 341
• 8 Lima LM, Barreiro EJ. Curr. Med. Chem. 2005; 12: 3
• 9a Boland GM, Donnelly DM. X. Nat. Prod. Rep. 1998; 12: 321
• 9b Militão CC. G, Prado MP, Pessoa C, De Moraes MO, Silveira ER, Lima MA. S, Veloso PA, Costa-Lotufo LV, Machado-Santelli GM. Biochimie 2014; 104: 147
• 10a Pterocarpens and 4-carba analogues present similar affinity for estrogenic receptors, see: Miller CP, Collini MD, Morris RL, Singhaus RR. U. S. Pat. Appl. Publ US 20060004087, 2006
• 10b Isoflavanones and 1-carba-isoflavanones present similar cytotoxic activity against some cancer cell lines (Pessoa C., Domingos J. L. O., Costa P. R. R. unpublished results) and similar anti-HCV properties, see: Manvar D, Fernandes TA, Domingos LO, Basu A, Junior EF. T, Baljinnyam E, Costa PR. R, Kaishik-Basu N. Eur. J. Med. Chem. 2015; 93: 51
• 11 Li J.-H, Hu X.-C, Liang Y, Xie Y.-X. Tetrahedron 2006; 62: 31
• 12 Razler TM, Hsiao Y, Qian F, Fu R, Khan RK, Doubleday W. J. Org. Chem. 2009; 74: 1381
• 13 Corma A, García H, Leyva A. J. Catal. 2006; 240: 87
• 14a Nabid MR, Bide H. J. Catal. 2014; 269: 183
• 14b Karami K, Moghadam ZK, Hosseini-Kharat M. Catal. Commun. 2014; 43: 25
• 15 Hauser FM, Prasanna S. Synthesis 1980; 621
• 16a da Silva AJ. M, Costa PR. R, Frota LC. R. M, Gomes RC. P. S. L. S. J. Braz. Chem. Soc. 2009; 20: 1916
• 16b For the preparation of 3d, the reaction must be isolated immediately after the addition of the complex iodine–morpholine because, in this case, longer reaction times led to a mixture of starting material and diiodinated product. See, also: Taber DF, Patel S, Hambleton TM, Winkel EE. J. Chem. Educ. 2007; 84: 1158
• 17 Frota LC. R. M, Costa PR. R, da Silva AJ. M, Militão GC. G. Patent WO2013040669-A1, 2013
• 18 Frota LC. R. M. Master Thesis . Novas Pterocarpanoquinonas; Síntese e Avaliação da Citotoxicidade, Universidade Federal do Rio de Janeiro: 2011
• 19 Firouzabadi H, Iranpoor N, Ghaderi A. Org. Biomol. Chem. 2011; 9: 865